Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYROC hypofractionated definitive chemoradiotherapy for oesophageal cancer
NL-OMON58480Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of carboplatin and paclitaxel in esophageal cancer and gastroesophageal junction adenocarcinoma, sponsored by Amsterdam University Medical Center. Primary endpoint: Feasibility and safety of hypofractionated definitive chemoradiotherapy. Started Apr 2026; status: recruiting.
02
Drugs
carboplatinpaclitaxel
03
Conditions
esophageal cancergastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON58480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58480.